Edwards Lifesciences Corp.

Board approves new stock repurchase program and $15M donation

Published in Cardiovascular Business Week, October 11th, 2005

Edwards Lifesciences Corp. (EW), a developer of products and technologies to treat advanced cardiovascular disease, announced that its board of directors authorized a new share repurchase program allowing the repurchase of up to 2 million shares of its outstanding common stock.

Additionally, the board approved a $15 million contribution to The Edwards Lifesciences Fund, a charitable fund.

"The new share repurchase program demonstrates our confidence in Edwards' future and enables us to offset the dilution of shares issued under our employee ownership programs," said Michael A. Mussallem, Edwards Lifesciences' chairman and CEO.

The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cardiovascular Business Week

Source: Cardiovascular Business Week (2005-10-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry